Enrique Grande, Head of Oncology at MD Anderson Cancer Center Madrid, shared a post on LinkedIn:
“Proud to finally share a paper that took a great deal of effort to write and get published.
Together with an international team, we conducted a global survey of 600+ uro-oncologists, gathering 201 responses from over 30 countries, to explore real-world use of enfortumab vedotin + pembrolizumab (EV-P) in metastatic urothelial carcinoma.
One of the largest initiatives of its kind to date.
EV-P has reshaped clinical practice, doubling survival in many patients and achieving ~30% complete responses with long-term durability.
But it also brings real-life challenges: pre-existing neuropathy, non-urothelial histology, poor performance status, or uncontrolled diabetes can increase toxicity risk – and these patients were not represented in pivotal trials.
The next step? Generating evidence for these high-risk groups and advancing more personalized, real-world oncology.”
Title: Guiding First-Line Treatment Decisions In Advanced Urothelial Carcinoma: A Global Survey
Authors: Enrique Grande, Joaquim Bellmunt, Syed A Hussain, Mubarak M Al Mansour, Aristotle Bamias, Philippe Barthélémy, David J Benjamin, Normand Blais, Maria T Bourlon, Daniel Castellano, Pongwut Danchaivijitr, Mauricio Fernandez Lazzaro, Patrizia Giannatempo, Félix Guerrero-Ramos, Roberto Iacovelli, Philipp Ivanyi, Eun Hee Jung, Ravindran Kanesvaran, Ray Manneh, Joana C Marinho, Nobuaki Matsubara, Axel S Merseburger, Deborah Mukherji, Chandler H Park, Ben Tran, Karine Martins da Trindade, Yüksel Ürün, Ashish M Kamat, Alison J Birtle
Read the Full Article.
More posts featuring Enrique Grande on OncoDaily.
